SEOUL (Reuters) – Shares in South Korean drug contract manufacturer Samsung BioLogics rose as much as 5.2% in early Monday trade, after it agreed to fill-finish manufacture Moderna’s COVID-19 vaccine.
The agreement was part of Moderna Inc and Novavax Inc entering into a deal with the South Korean government to manufacture their COVID-19 vaccines.
The wider market was down 0.2% as of 0007 GMT.
(Reporting by Joyce Lee; Editing by Tom Hogue)
